Hybrid Meeting 2021
Thursday, 18 November 2021
Royal College of Physicians of Edinburgh
Overview
SHARP for over 30 years has been at the forefront of the prevention of cardiovascular disease in Scotland. As we emerge from the effects of the COVID-19 pandemic our exciting educational programme continues with our November 2021 meeting.
Atrial fibrillation is a major risk factor for stroke. We will address both its detection and management, how to balance the benefit of prevention versus the risks and what is new in respect of national clinical guidance. The long term mortality and morbidity effects of coronary artery disease remains a major problem for society so it is both appropriate and important using a personalised approach, to examine recent therapeutic developments of heart failure in improving clinical outcomes.
We have become accustomised in the past two years to the benefits of technology enhanced consulting but wearable technology in the detection of heart disease continues to develop apace. Those attending the meeting will learn the role of technology in diagnosis and importantly what to do when faced with a printout from a patient using the latest ‘gizmo’.
We always need to look forward and more especially after a difficult two years. We are fortunate to have as a speaker, a worldwide expert of how the use of data will inform the management of patients with heart and vascular disease in the years ahead.
Finally, we are very proud of our continuing role in promoting the SHARP prize in the field of cardiovascular disease in order to showcase the work of young health professionals and helping to support and enhance their careers.
Sponsors
This event was funded by the companies mentioned through event sponsorship and sponsored sessions for which we are very grateful.
Other than their own sessions, these companies had no input into the design or content of the agenda but were in attendance on the day. Furthermore, the Bristol-Myers Squibb/Pfizer Alliance had funded and organised the sponsored lunchtime session on the agenda.
Presentations
Causal AI: Personalizing Estimation of Cardiovascular Risk based on Cumulative Exposure to the Causes of Atherosclerosis
Professor Brian Ference
Director of Research (Professor) in Translational Therapeutics & Executive Director of the Centre for Naturally Randomized Trials, University of Cambridge
Presentation by
Debate: Should Scotland adopt the 2019 ESC/EAS guidelines for lipid management?
Professor Chris Packard & Dr Michael Murphy
Professor Packard: Honorary Senior Research Fellow, Institute of CV & Medical Sciences, University of Glasgow
Dr Murphy: Clinical Reader, School of Medicine, University of Dundee
Presentation by
David on Goliath’s shoulders – how big data will inform healthcare
Professor Calum MacRae
Executive Director, One Brave Idea, PI, Apple Heart & Movement Study
Presentation by
SHARP Prize
Audit of patient selection for Familial Hypercholesterolaemia (FH) genetic testing over a 2-year period with retrospective comparison of the Simon-Broome criteria vs the Dutch Lipid Clinic Network (DLCN) criteria vs the Wales FH service genotype scoring criteria
Ruey Ping (Bernice) Teo
School of Medicine, University of Dundee, Dundee, UK
Winner of Best Poster for Lipid Theme
